drugset / Trial / NCT02733380

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

NCT02733380

Phase 2 Unknown 20 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with VDDT(vinorelbine,liposomal doxorubicin,dexamethasone and thalidomide) in relapsed and refractory patients with diffuse large B-cell lymphoma(DLBCL).

Timeline

Start
2016-05
Primary completion
2020-05
Completion
2021-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 30 mg Oral
Background Dexamethasone Small molecule 10 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 20 mg/m2 Intravenous
Background Mitoxantrone Small molecule 8 mg/m2 Intravenous
Background Thalidomide Other / unclassified 100 mg Oral
Background Vinorelbine Small molecule 20 mg/m2 Intravenous